By PPN News Staff
The FDA approved maribavir (Livtencity, Takeda) to treat adults and children at least 12 years of age and weighing at least 35 kg with post-transplant cytomegalovirus (CMV) infection that does not respond to other antiviral treatments.
The medication can be used regardless of whether genetic mutations that cause resistance are present.
Maribavir’s safety and efficacy were evaluated in the phase 3, global, multicenter, open-label, active-controlled SOLSTICE trial